3-bromo-4-chloro-1-[(4-methoxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridine, 97.0%, 100mg

2-Methyl-5-(trifluoromethyl)pyridine, 97.0%, 250mg

2-QUINOXALINECARBOXYLIC ACID, 6-NITRO-, ETHYL ESTER, 96.0%, 250mg

(3aS,8aR)-2-(Quinolin-2-yl)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole, 97%, 250mg

3-Chloro-5-hydroxybenzoic Acid>98.0%(GC)(T)1g

GC capillary column ROTI®Cap-1701, 25 m, 0.53 mm, 2.00 µm, 1 Piece(s)

(3'-Fluoro[1,1'-biphenyl]-3-yl)methanol, 1g

(((9H-Fluoren-9-yl)methoxy)carbonyl)-D-tyrosine, 95%, 100g

2-(1-(tert-butoxycarbonyl)pyrrolidin-3-yl)benzoic acid, 95.0%, 100mg

2,5-Dimethylbenzo[d]oxazole, 95.0%, 25g

N-Boc-5-Bromoanthranilic acid, 95.0%, 5g

4-Quinazolinamine, N-(1-cyclohexyl-4-piperidinyl)-2-[hexahydro-4-(1-methylethyl)-1H-1,4-diazepin-1-yl]-6-methoxy-7-[3-(1-piperidinyl)propoxy]-, 98%, 5mg

Bis(8-quinolinolato)zinc(II) Hydrate>93.0%(T)5g